Midazolam
Keep this leaflet, you may need to read it again.
In case of any doubts, consult a doctor, pharmacist, or nurse.
This medication has been prescribed for a specific person. Do not pass it on to others.
The medication may harm another person, even if their symptoms are the same.
If the patient experiences any side effects, including those not listed in this leaflet, they should inform their doctor, pharmacist, or nurse.
See section 4.
Midazolam Sandoz contains the active substance midazolam and belongs to a group of medicines called benzodiazepines. Midazolam is a short-acting medication that causes sedation (a state of calm, drowsiness, or sleep) and relieves anxiety and muscle tension. It has anticonvulsant properties and causes amnesia for recent events.
If:
the patient is allergicto:
Midazolam Sandoz should only be used when appropriate resuscitation equipment is available, tailored to the patient's age and size, due to the possibility of life-threatening side effects, see also section 4. Administration of Midazolam Sandoz may inhibit cardiac muscle contractions and cause apnea (a pause in breathing). Severe cardiovascular and respiratory side effects are possible, including respiratory depression, apnea, respiratory arrest, and (or) cardiac arrest. To avoid such events, the medication should be administered slowly and in the smallest possible dose.
If Midazolam Sandoz is used for premedication, the doctor will carefully monitor the patient's reaction to ensure the correct dose is administered, as sensitivity to the medication varies between patients.
During the use of Midazolam Sandoz, paradoxical reactions and anterograde amnesia (loss of memory of recent events) have been reported, see section 4.
Prolonged use
If Midazolam Sandoz is used for a long time, the patient may develop tolerance (reduced effectiveness of the medication) or dependence on the medication.
After prolonged treatment (e.g., in an intensive care unit), the patient may experience withdrawal symptoms. To avoid them, the doctor will gradually reduce the dose of the medication. Further information can be found in section 3: "Discontinuation of Midazolam Sandoz".
Before using Midazolam Sandoz, the patient should discuss with their doctor or nurse if they:
Using Midazolam Sandoz in infants or children requires special caution.
Consult a doctor or nurse if the child is to receive this medication and:
Tell your doctor or nurse about all medications you are currently taking or have recently taken.
Tell your doctor or nurseif you are taking any of the following medications, as they may enhance the effect of Midazolam Sandoz:
sedatives, sleeping pills, muscle relaxants, or medications used to treat anxiety and mental disorders
medications that facilitate sleep or are used in anesthesia, such as etomidate, ketamine, propofol
medications used to treat mental disorders or anxiety, with a sedative effect
medications used to treat depression
carbamazepine or phenytoin (medications that may be administered in case of seizures or epilepsy)
medications used to treat severe pain or cough, or used in substitution therapy
medications used to treat allergies and sleep disorders (so-called antihistamines)
medications used to treat fungal infections, with active substance names ending in "azol", such as ketoconazole, voriconazole, fluconazole, itraconazole, posaconazole
medications used to treat bacterial infections, with active substance names ending in "mycin", such as erythromycin, clarithromycin
diltiazem: a medication used to treat high blood pressure and heart disorders
medications used to treat high blood pressure, acting on the brain
medications used to treat HIV infections, with active substance names ending in "navir", such as saquinavir
medications used to treat hepatitis C, with names ending in "previr", such as boceprevir, telaprevir
atorvastatin: a medication used to reduce cholesterol levels
rifampicin: a medication used to treat tuberculosis
St. John's Wort: a herbal remedy used to treat depression
inhalation anesthetics
While using Midazolam Sandoz, do not drink alcohol. Alcohol may significantly enhance the sedative effect of this medication and cause breathing difficulties.
This medication contains less than 1 mmol (23 mg) of sodium per ml, which means it is considered "sodium-free".
This medication should only be administered by an experienced doctor or nurse. It is administered in a hospital, clinic, or surgical office, with the possibility of:
The doctor determines the dose individually for the patient, depending on:
Children over 12 years old usually receive the medication intravenously. Rectal administration is also possible if the goal is to sedate before anesthesia. Refer to the information in section 2 under "Children".
Midazolam Sandoz is compatiblewith the following infusion solutions:
Midazolam Sandoz is notcompatible with the following infusion solutions:
To avoid possible incompatibility, Midazolam Sandoz should not be mixed with other solutions, except those listed above.
Ampoules of Midazolam Sandoz are for single use. Any unused product should be discarded.
Before administration, the ampoule and solution should be inspected. Only undamaged ampoules and clear solutions without solid particles and without color change should be used.
If the patient experiences the following overdose symptoms, they should inform their doctor, who will provide appropriate treatment:
Overdose may require close monitoring of vital functions, symptomatic treatment of cardiovascular and respiratory effects, and the use of a benzodiazepine antagonist.
If Midazolam Sandoz has been used for a long time:
If the treatment is stopped suddenly or the dose is reduced too quickly, the patient may experience the following withdrawal symptoms:
The doctor will gradually reduce the dose of the medication to avoid these symptoms.
In case of any further doubts about the use of this medication, consult a doctor or nurse.
Like all medications, this medication can cause side effects, although not everybody gets them.
The following side effects may occur during the use of this medication. Their frequency is unknown (cannot be estimated from the available data).
reduced alertness
confusion
excessive feeling of happiness or excitement (euphoria)
changes in sex drive
fatigue, drowsiness, and prolonged sedation
seeing or hearing things that do not exist (hallucinations)
headache
dizziness
coordination disorders
seizures in premature infants and newborns
temporary memory loss. The duration of memory loss depends on the duration of treatment and the dose administered. It may persist after the end of treatment, in individual cases for a long time.
anxiety, hostility, anger, or aggression. Uncontrolled muscle spasms or muscle tremors may also occur. The likelihood of their occurrence is higher if the patient received a high dose of Midazolam Sandoz or if the medication was administered too quickly, as well as in children and the elderly.
If the patient notices that they are becoming dependent on the medication or the medication is becoming less effective and the dose needs to be increased, they should inform their doctor.
slow heartbeat
cardiac arrest
flushing of the face and neck
fainting
low blood pressure (may cause dizziness or fainting)
formation of a blood clot or vein inflammation (thrombophlebitis)
hiccups
shortness of breath, lack of breath
dry mouth
constipation
nausea, vomiting
itching
rash, hives
redness of the skin and pain at the injection site
allergic reactions, including rash and wheezing
withdrawal symptoms (see "Discontinuation of Midazolam Sandoz" in section 3)
falls and bone fractures. The risk of their occurrence is higher if the patient is taking other medications that cause drowsiness (e.g., sedatives or sleeping pills) or if the patient is also drinking alcohol.
The risk of falls and bone fractures is higher in the elderly who receive benzodiazepines, such as Midazolam Sandoz.
In people over 60 years old, the likelihood of life-threatening side effects is higher.
If side effects occur, including those not listed in this leaflet, the patient should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw
tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medication.
Store the medication out of sight and reach of children.
Do not use this medication after the expiration date stated on the ampoule and carton after EXP. The expiration date is the last day of the given month.
Store in the original packaging to protect from light.
After opening the ampoule
For microbiological reasons, the medication should be used immediately. If not, the user is responsible for the storage conditions and time before use.
After dilution
Chemical and physical stability of the diluted solutions has been demonstrated for 24 hours at room temperature (15-25°C) or for 3 days at a temperature of +2°C to +8°C.
From a microbiological point of view, the medication should be used immediately after dilution. If not, the user is responsible for the storage conditions and time before use, but this time should not exceed 24 hours, and the temperature should be between +2°C and +8°C, unless the dilution was performed in controlled and validated aseptic conditions.
Ampoules of Midazolam Sandoz are for single use. Any unused product should be discarded.
Do not use this medication if the ampoule is not intact or the solution is not free from solid particles or has changed color.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medications that are no longer needed. This will help protect the environment.
The active substance of the medication is midazolam.
Midazolam Sandoz1 mg/ml
Each 5 ml ampoule of solution for injection or infusion contains 5 mg of midazolam (as midazolam hydrochloride).
Midazolam Sandoz5 mg/ml
Each 1 ml ampoule of solution for injection or infusion contains 5 mg of midazolam (as midazolam hydrochloride).
Each 3 ml ampoule of solution for injection or infusion contains 15 mg of midazolam (as midazolam hydrochloride).
Each 10 ml ampoule of solution for injection or infusion contains 50 mg of midazolam (as midazolam hydrochloride).
Other ingredients are:
Midazolam Sandoz 1 mg/ml: sodium chloride, hydrochloric acid, water for injections.
Midazolam Sandoz 5 mg/ml: sodium chloride, hydrochloric acid, sodium hydroxide, water for injections.
This medication is a clear, light yellow solution in a clear glass ampoule.
Pack sizes:
Midazolam Sandoz 1 mg/ml
5 x 5 ml
Midazolam Sandoz 5 mg/ml
5 x 1 ml
5 x 3 ml
5 x 10 ml
Marketing authorization holder
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl, Austria
Manufacturer
Salutas Pharma GmbH
Otto-von-Guericke-Allee 1
39179 Barleben, Germany
Sandoz GmbH
Biochemiestrasse 10
6250 Kundl
Austria
EVER Pharma Jena GmbH
Otto-Schott-Straße 15
7745 Jena
Germany
Ever Pharma Jena GmbH
Brüsseler Straße 18
07747 Jena
Germany
Sandoz Polska Sp. z o.o.
ul. Domaniewska 50 C
02-672 Warsaw
tel. 22 209 70 00
Date of last revision of the leaflet:08/2023
Sandoz logo
Preparation of the infusion solution
Midazolam Sandoz can be diluted with 0.9% sodium chloride solution, 5% (50 mg/ml) glucose solution, or 10% (100 mg/ml) glucose solution, Ringer's solution, or Hartmann's solution in a ratio of 15 mg of midazolam per 100 to 1000 ml of infusion solution. These solutions remain stable for 24 hours at room temperature and for 3 days at a temperature of +2°C to +8°C.
Midazolam Sandoz should not be mixed with other solutions except those listed above.
In particular, Midazolam Sandoz should not be mixed with 6% (w/v) dextran solution (with 0.9% sodium chloride solution) in dextrose or with alkaline injection solutions. Midazolam precipitates in a solution containing sodium bicarbonate.
Ampoules and solution should be inspected before administration. Only undamaged ampoules and clear solutions without solid particles and without color change should be used.
Shelf life and storage
Ampoules of Midazolam Sandoz are for single use.
Ampoules before opening
Store in the outer packaging to protect from light.
Ampoules after dilution
Chemical and physical stability of the diluted solutions has been demonstrated for 24 hours at room temperature (15-25°C) or for 3 days at a temperature of +2°C to +8°C.
From a microbiological point of view, the medication should be used immediately after dilution. If not, the user is responsible for the storage conditions and time before use, but this time should not exceed 24 hours, and the temperature should be between +2°C and +8°C, unless the dilution was performed in controlled and validated aseptic conditions.
When administering as a continuous intravenous infusion, the solution can be diluted with one of the above-mentioned solutions to achieve a final concentration in the range of 0.015 to 0.15 mg.
Disposal of waste
Any unused product or waste should be disposed of in accordance with local regulations.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.